"The health and safety of our patients, visitors, employees, and our communities remain a top priority at NewYork-Presbyterian. In response to the evolving COVID-19 outbreak and in line with our revised General Visitation Guidelines, we are keeping select entrances open at each Hospital throughout the enterprise. All other entrances will be closed and inaccessible to patients, visitors, and staff. The following entrances will remain open for patients, visitors, and employees: Main and Emergency Department Entrances"

During the past decade, New York Presbyterian/Queens conducted 57 clinical trials. In the 10-year time frame, 57 clinical trials started and 31 clinical trials were completed, i.e. on average, 54.4% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 16 clinical trials were completed. i.e. 48.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Presbyterian/Queens" #1 sponsor was "Weill Medical College of Cornell University" with 17 trials, followed by "Gilead Sciences" with 11 trials sponsored, "Alliance for Clinical Trials in Oncology" with 5 trials sponsored, "National Cancer Institute (NCI)" with 5 trials sponsored and "NRG Oncology" with 5 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Presbyterian/Queens" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 7 trials as a collaborator, "NRG Oncology" with 4 trials as a collaborator, "United States Department of Defense" with 4 trials as a collaborator and "Canadian Cancer Trials Group" with 3 trials as a collaborator. Other collaborators include 91 different institutions and companies that were collaborators in the rest 94 trials.

According to Clinical.Site data, the most researched conditions in "New York Presbyterian/Queens" are "Breast Cancer" (7 trials), "HIV Infections" (6 trials), "Endometrial Clear Cell Adenocarcinoma" (4 trials), "Endometrial Serous Adenocarcinoma" (4 trials) and "Atrial Fibrillation" (3 trials). Many other conditions were trialed in "New York Presbyterian/Queens" in a lesser frequency.

Most popular intervention types in "New York Presbyterian/Queens" are "Drug" (51 trials), "Other" (25 trials), "Radiation" (17 trials), "Biological" (12 trials) and "Procedure" (9 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (11 trials), "Quality-of-Life Assessment" (11 trials), "Carboplatin" (10 trials), "Placebo" (7 trials) and "Questionnaire Administration" (6 trials). Other intervention names were less common.

The vast majority of trials in "New York Presbyterian/Queens" are 55 trials for "All" genders, 30 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "New York Presbyterian/Queens". undefined are not yet recruiting, 26 are recruiting, 15 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 35 completed trials in New York Presbyterian/Queens, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in New York Presbyterian/Queens, 2 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 15 trials that are defined as “Not Applicable".